Cyclerion Therapeutics Inc (CYCN)

Currency in USD
3.390
+0.035(+1.04%)
Closed·
3.3900.000(0.00%)
·
CYCN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.2803.480
52 wk Range
1.0278.480
Key Statistics
Prev. Close
3.355
Open
3.28
Day's Range
3.28-3.48
52 wk Range
1.027-8.48
Volume
15.65K
Average Volume (3m)
4.58M
1-Year Change
9.3548%
Book Value / Share
1.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CYCN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cyclerion Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 12, 2026
EPS / Forecast
-0.76 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CYCN Income Statement

Compare CYCN to Peers and Sector

Metrics to compare
CYCN
Peers
Sector
Relationship
P/E Ratio
−2.7x5.2x−0.4x
PEG Ratio
0.10−0.320.00
Price/Book
2.1x3.7x2.6x
Price / LTM Sales
7.2x3.8x3.0x
Upside (Analyst Target)
136.0%110.3%53.6%
Fair Value Upside
Unlock25.4%7.6%Unlock

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
392.39K9.25%1.32M
Other Institutional Investors
909.05K21.43%3.05M
Public Companies & Retail Investors
2.94M69.31%9.86M
Total
4.24M100.00%14.23M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC15.31%649,5472,179
Fidelity Select Portfolios - Health Care Portfolio4.84%205,108688

People Also Watch

11.07
REPL
-1.16%
31.560
CUE
+3.71%
3.270
LNAI
+3.15%
13.040
EVC
-3.26%
4.21
IRWD
-2.09%

FAQ

What Is the Cyclerion Therapeutics (CYCN) Stock Price Today?

The Cyclerion Therapeutics stock price today is 3.390 USD.

What Stock Exchange Does Cyclerion Therapeutics Trade On?

Cyclerion Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Cyclerion Therapeutics?

The stock symbol for Cyclerion Therapeutics is "CYCN."

What Is the Cyclerion Therapeutics Market Cap?

As of today, Cyclerion Therapeutics market cap is 14.380M USD.

What Is Cyclerion Therapeutics's Earnings Per Share (TTM)?

The Cyclerion Therapeutics EPS (TTM) is -1.468.

From a Technical Analysis Perspective, Is CYCN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cyclerion Therapeutics Stock Split?

Cyclerion Therapeutics has split 1 times.

How Many Employees Does Cyclerion Therapeutics Have?

Cyclerion Therapeutics has 1 employees.

What is the current trading status of Cyclerion Therapeutics (CYCN)?

As of Jul 01, 2026, Cyclerion Therapeutics (CYCN) is trading at a price of 3.390 USD, with a previous close of 3.355 USD. The stock has fluctuated within a day range of 3.280 USD to 3.480 USD, while its 52-week range spans from 1.027 USD to 8.480 USD.

What Is Cyclerion Therapeutics (CYCN) Price Target According to Analysts?

The average 12-month price target for Cyclerion Therapeutics is 8.000 USD, with a high estimate of 8 USD and a low estimate of 8 USD. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +135.99% Upside potential.

What Is the CYCN Premarket Price?

CYCN's last pre-market stock price is 3.340 USD. The pre-market share volume is 10.000, and the stock has decreased by -0.015, or -0.450%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.